ZIA BC 011219 (ZIA) | |||
---|---|---|---|
Title | Combination Gene Therapy and Th1/Th2 Therapy | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Fowler, Daniel | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $267,157 | Project Dates | 10/01/2008 - 00/00/0000 |
Fiscal Year | 2014 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Bone Marrow Transplantation (50.0%) Cancer (100.0%) Gene Therapy (50.0%) |
Leukemia (50.0%) Non Hodgkins Lymphoma (50.0%) |
||
Research Type | |||
Systemic Therapies - Discovery and Development Systemic Therapies - Clinical Applications |
|||
Abstract | |||
We have focused our efforts on the use of lentiviral vectors to transfer genes to the rapamycin-resistant T cells. Using this approach, the majority of T cells in a given culture can be induced to express the new gene. We have also developed animal models to test the in vivo effect of these immuno-gene therapy strategies. Such models incorporate tumors and also evaluate graft-versus-host disease, which remains the main complication after allogeneic hematopoietic stem cell transplantation. To facilitate implementation of this project, we have entered into a cooperative research agreement with Lentigen Corporation to develop clinical protocols focusing on lentiviral delivery of suicide genes. Relevant cancer sites: Non-Hodgkins Lymphoma, Leukemia. Relevant Research Areas: Gene Therapy, Bone Marrow Transplantation, Organ Transplantation Research, Combined Treatment Modalities, Hematology/Lymph." |